Drugs Made In America Acquisition II Corp. DMII
$10.16
-$0.01-0.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 4.40M | 4.34M | 4.33M | -46.20K | -38.10K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.51M | -4.47M | -4.57M | -78.70K | 47.20K |
| Change in Net Operating Assets | -60.50K | 29.50K | -79.40K | -565.80K | -11.70K |
| Cash from Operations | -172.70K | -102.50K | -314.90K | -690.70K | -2.60K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 0.00 | -500.00M | -- |
| Cash from Investing | -- | -- | 0.00 | -500.00M | -- |
| Total Debt Issued | 0.00 | 450.00K | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00 | -533.80K | -- |
| Issuance of Common Stock | -- | -- | 0.00 | 502.00M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | -464.80K | -- |
| Cash from Financing | 0.00 | 450.00K | 0.00 | 501.00M | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -172.70K | 347.50K | -314.90K | 310.70K | -2.60K |